The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
In a quiet year for medical devices a couple of studies are still worth watching.
Big cap medtech is hiring, largely thanks to organic growth.
The preponderance of large deals comes partly as a consequence of soaring market valuations; paradoxically, it is also a cause of them.